C₂₂₅H₃₄₈F₂N₄₈O₆₈ · 4813.45 g/mol

Tirzepatide

Tirzepatide is a 39-amino acid synthetic peptide and the first-in-class dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. The compound is built on a modified GIP backbone with substitutions enabling balanced activity at both incretin receptors plus a C20 fatty diacid moiety supporting once-weekly research dosing. Developed by Eli Lilly, tirzepatide has demonstrated superior weight-loss and glycemic effects compared to single-receptor GLP-1 agonists in the SURPASS and SURMOUNT clinical trial programs. Research applications focus on combined incretin pathway modulation, energy expenditure, and metabolic syndrome models.